Regorafenib clinical trials
Also written Stivarga and BAY 73-4506.
How each study uses regorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the regorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Sept 2012 · STIVARGA · NDA 203085 (FDA, Drugs@FDA)
- European Union
- 26 Aug 2013 · Stivarga · EMEA/H/C/002573 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
173 studies that test it; most in 2014 (22)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 1 |
| 2013 | 15 |
| 2014 | 22 |
| 2015 | 18 |
| 2016 | 16 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 12 |
| 2020 | 10 |
| 2021 | 12 |
| 2022 | 10 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 6 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 40 · Other 133
Bayer (32) · Asan Medical Center (5) · Academic and Community Cancer Research United (4) · Memorial Sloan Kettering Cancer Center (4) · Centre Hospitalier Universitaire de Besancon (3) · Australasian Gastro-Intestinal Trials Group (3) · Istituto Oncologico Veneto IRCCS (3) · UNICANCER (3)
Often tested with
Tested in the same studies.
Nivolumab (15) · Durvalumab (4) · Irinotecan (4) · Trametinib (4) · Pembrolizumab (4) · Cabozantinib (4) · Capecitabine (3) · Cetuximab (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Regorafenib is the comparator. A study of two new drugs counts under both.
- 1Zanzalintinib · Exelixis
- 1Becotatug · Shanghai JMT-Bio Inc. · next primary completion Jun 2027
Reaching primary completion within a year · 10
Studies that test regorafenib.
- Nov 2026Dose-escalation of Regorafenib in Advanced Hepatocellular CarcinomaPhase 2 · Instituto do Cancer do Estado de São Paulo
- Dec 2026A Clinical Trial of Regorafenib in Patients With Pretreated Advanced MelanomaPhase 2 · Universitair Ziekenhuis Brussel
- Dec 2026Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerPhase 2 · Jules Bordet Institute
- Dec 2026ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTPhase 2 · University of Miami
- Feb 2027A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Mar 2027GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.Phase 2 · Chinese PLA General Hospital
- Apr 2027Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing SarcomaPhase 1 · Gustave Roussy, Cancer Campus, Grand Paris
- Sep 2027Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal CancersPhase 2 · Centre Hospitalier Universitaire de Besancon
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Sep 2027An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibPhase 2 · Incyte Corporation
Studies
Open first, then newest update. How each study uses regorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 173
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Regorafenib
- Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal CancersRecruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT06425133Written as Regorafenib
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Regorafenib
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingPhase 2University of MiamiNCT05366816Written as Regorafenib
- STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal CancerRecruitingPhase 2National Cancer Institute, NaplesNCT07213570Written as Regorafenib (BAY73-4506)
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT06887218Written as Regorafenib (BAY 73-4506)
- Regorafenib for Recurrent Meningioma (MIRAGE Trial)RecruitingPhase 2Istituto Oncologico Veneto IRCCSNCT06275919Written as Regorafenib 40 MG Oral Tablet
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07750041Written as Regorafenib
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Regorafenib
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingPhase 2Asan Medical CenterNCT07495579Written as regorafenib
- Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma PatientsNot yet recruitingPhase 2Ju Hyun ShimNCT07514455Written as Regorafenib (BAY 73-4506)
- Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC TrialNot yet recruitingPhase 2Ju Hyun ShimNCT07514429Written as Regorafenib (BAY 73-4506)
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasRecruitingNot applicableCentre Leon BerardNCT04055220Written as Treatment by Regorafenib
- GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.RecruitingPhase 2Chinese PLA General HospitalNCT06558773Written as Regorafenib+Immune checkpoint inhibitor
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 2Sarah K. Lynam MDNCT05113368Written as Regorafenib
- Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07078305Written as Regorafenib and tislelizumab
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06992648Written as Trifluridine/Tipiracil + Regorafenib
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingPhase 2Humanity & Health Medical Group LimitedNCT03899428Written as Regorafenib
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaRecruitingPhase 1/2University of BirminghamNCT04625907Written as Regorafenib
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingPhase 1China Medical University, ChinaNCT06283303Written as regorafenib
See all 173 studies that test regorafenib →
Given beside what is tested · 66 — regorafenib is usual care or a partner of the new treatment
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingPhase 2/3Ningbo Newbay Technology Development Co., LtdNCT07379047Written as regorafenib
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingPhase 1/2Neonc Technologies, Inc.NCT06047379Written as Regorafenib
- A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07730489Written as Regorafenib
- Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]RecruitingPhase 2M.D. Anderson Cancer CenterNCT07071961Written as Regorafenib (CT)
- Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRecruitingPhase 1West China HospitalNCT07567222Written as Regorafenib
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingPhase 2Jian LiNCT07559864Written as Regorafenib + Envafolimab
- TATE and Pembrolizumab (MK3475) in mCRC and NSCLCRecruitingPhase 2Teclison Ltd.NCT04701476Written as Regorafenib Pill
- A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingPhase 1Zhejiang UniversityNCT05155189Written as Regorafenib (BAY 73-4506)
- Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.RecruitingEarly Phase 1JIANG LONGWEINCT07343791Written as DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingPhase 1China Medical University, ChinaNCT06283134Written as regorafenib
- Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07148427Written as Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
- Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingPhase 2Fudan UniversityNCT07100392Written as Regorafenib
- A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard TreatmentNot yet recruitingPhase 2Peking UniversityNCT06772233Written as regorafenib combined with envafolimab
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingPhase 2Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityNCT06280105Written as Cadonilimab+regorafenib
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingPhase 2Fudan UniversityNCT05057052Written as Regorafenib
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"RecruitingPhase 2Beijing Friendship HospitalNCT06829355Written as Regorafenib (BAY 73-4506)
- Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRCRecruitingNot applicableThe First People's Hospital of ChangzhouNCT06456515Written as Regorafenib and Sintilimab in combination with electroacupuncture
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Not yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611Written as Regorafenib
- Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT05963490Written as Regorafenib
- Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingPhase 2Jin-hong ChenNCT06455254Written as Regorafenib
Showing 20 of 66.
As the comparator · 24 — what is tested is compared with regorafenib
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07857135Written as Regorafenib
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingPhase 2Fudan UniversityNCT07328009Written as Regorafenib (BAY 73-4506)
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2/3Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT07392866Written as Regorafenib
- Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular CarcinomaRecruitingPhase 2Zhejiang Hisun Pharmaceutical Co. Ltd.NCT07310173Written as Regorafenib Tablets
- The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal CancerNot yet recruitingPhase 3Shanghai JMT-Bio Inc.NCT07134205Written as Regorafenib
- Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS GenesRecruitingPhase 2Sergey Orlov, MDNCT06949982Written as Regorafenib (BAY 73-4506)
- A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06089330Written as Regorafenib (Stivarga)
- Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver MetastasesRecruitingPhase 3Sun Yat-sen UniversityNCT05794971Written as Regorafenib
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationCompletedPhase 3AmgenNCT05198934Written as Regorafenib
- Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingPhase 3ExelixisNCT05425940Written as Regorafenib
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)CompletedPhase 3Merck Sharp & Dohme LLCNCT05064059Written as regorafenib
- Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNot applicableSun Yat-sen UniversityNCT07537985Written as Regorafenib
- Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT04776148Written as regorafenib
- Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular CarcinomaActive, not recruitingPhase 2/3Xi'an Xintong Pharmaceutical Research Co.,Ltd.NCT07300488Written as regorafenib
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedPhase 3Merck Sharp & Dohme LLCNCT05600309Written as regorafenib
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedPhase 1/2Arcus Biosciences, Inc.NCT04660812Written as Regorafenib
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabCompletedPhase 3Ludwig-Maximilians - University of MunichNCT02934529Written as regorafenib
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal CancerCompletedPhase 2EpicentRx, Inc.NCT02096354Written as Regorafenib
- Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerActive, not recruitingPhase 2Academic and Community Cancer Research UnitedNCT03992456Written as Regorafenib
- Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal CancerCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT02316340Written as Regorafenib
Showing 20 of 24.
Codes
What other systems call regorafenib · ClinicalTrials.gg INT005858
- MeSH (NLM) C559147regorafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MGN125FS9DREGORAFENIBConfirmed FDA, Wikidata
- RxNorm 1371319Confirmed FDA, Wikidata
- Wikidata Q27137075regorafenib monohydrateConfirmed FDA, Wikidata
- NCI Thesaurus C184955RegorafenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C559147 | regorafenib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MGN125FS9D | REGORAFENIB | Confirmed FDA, Wikidata |
| RxNorm | 1371319 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27137075 | regorafenib monohydrate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C184955 | Regorafenib | One source FDA |
Also registered as regorafenib anhydrous (UNII 24T2A1DOYB · RxNorm 1312397).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.